Pain management

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

Retrieved on: 
Dienstag, April 16, 2024
FDA, Public, PNS, Pancreatic cancer, Health, Survival, Orphan, AMIX, CADL, Pain management, Patient, Peripheral nervous system, TAMP, Therapy, Electrophysiology, Pharmaceutical industry

The Benzinga article delves into the critical role of the PNS in human health and highlights how Autonomix Medical is pioneering with its catheter-based microchip sensing array technology.

Key Points: 
  • The Benzinga article delves into the critical role of the PNS in human health and highlights how Autonomix Medical is pioneering with its catheter-based microchip sensing array technology.
  • The article provides a comprehensive look at how Autonomix Medical is redefining treatment protocols for nerve-related disorders.
  • This approach, likened to a "GPS" for nerve treatment, allows for precise identification and treatment of the nerves involved, enhancing the accuracy and effectiveness of procedures.
  • Note: The details provided in this press release are based on information featured in the Benzinga article and do not constitute forward-looking statements.

Englewood Hospital Named a Top Hospital in New Jersey by Jersey's Best Magazine

Retrieved on: 
Donnerstag, Mai 9, 2024
Best, Knee, Stroke, Hospital, Bed, Communication, Partnership, Patient, Prostate cancer, Pain management, DSM-IV codes, Empathy, Castle Connolly Medical, Breast cancer, Heart

ENGLEWOOD, N.J., May 9, 2024  /PRNewswire/ -- Englewood Hospital has been named a top hospital in New Jersey by Jersey's Best magazine. 

Key Points: 
  • Among the top 82 hospitals ranked in New Jersey, Englewood Hospital was the highest-ranking hospital in Bergen County.
  • ENGLEWOOD, N.J., May 9, 2024 /PRNewswire/ -- Englewood Hospital has been named a top hospital in New Jersey by Jersey's Best magazine.
  • In partnership with Castle Connolly Top Doctors, Jersey's Best magazine awarded Top Hospital designations for hospitals with more than 350 beds, and for those with 350 beds or fewer.
  • All told, 82 hospitals across New Jersey were ranked and Englewood Hospital was the highest-ranking hospital in Bergen County in the category of 350+ beds.

EUDA Health Expands into Direct Selling Holistic Wellness Products with Acquisition of CK Health

Retrieved on: 
Montag, Mai 6, 2024
Digestion, Genetics, Inflammation, Neuroscience, Weight loss, DNA, Pain management, Acquisition, CK, Bioenergy

SINGAPORE, May 06, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it will acquire CK Health Plus Sdn Bhd (“CK Health”), a direct seller of holistic wellness consumer products in Malaysia.

Key Points: 
  • SINGAPORE, May 06, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it will acquire CK Health Plus Sdn Bhd (“CK Health”), a direct seller of holistic wellness consumer products in Malaysia.
  • Established in Malaysia in 2023, CK Health is a direct seller of holistic wellness consumer products through its online platform and member network.
  • CK Health’s products leverage non-invasive therapies to make holistic healthcare accessible for everyone using advanced technologies.
  • Through CK Health, EUDA will license bioenergy cabins to partners such as spas, beauty salons, and confinement centers and will distribute Yoroyal’s consumer products through direct selling, e-commerce platforms, and retail outlets.

InfuSystem Reports First Quarter 2024 Financial Results

Retrieved on: 
Donnerstag, Mai 9, 2024
Practice Management, Medical Supplies, Oncology, General Health, Health, Medical Devices, Hospitals, Other Health, Risk, Depreciation, Forecasting, Capital expenditure, Information technology, Pain management, Form 10-K, Marketing, Bank statement, Adjustment, Annual report, Credit, History, Absorption, GAAP, G&A, NPWT, Pharmaceutical industry

InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2024.
  • Net revenues for the quarter ended March 31, 2024 ("2024 First Quarter") were $32.0 million, an increase of $1.6 million, or 5%, compared to $30.4 million for the quarter ended March 31, 2023 ("2023 First Quarter").
  • Patient Services net revenue of $18.6 million decreased $0.2 million, or 1.0%, during the 2024 First Quarter compared to the 2023 First Quarter.
  • The Company will conduct a conference call for all interested investors on Thursday, May 9, 2024, at 9:00 a.m. Eastern Time to discuss its first quarter 2024 financial results.

Zynex Executives Recognized Among Top 25 in Medical Technology

Retrieved on: 
Dienstag, Mai 7, 2024
Zynex, Sale, Culture, Rehabilitation, Pain management, Health technology, Management

ENGLEWOOD, Colo., May 7, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today is proud to announce that two of our executives have been featured among Medical Technology's Top 25 by The Healthcare Technology Report .

Key Points: 
  • ENGLEWOOD, Colo., May 7, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today is proud to announce that two of our executives have been featured among Medical Technology's Top 25 by The Healthcare Technology Report .
  • Anna Lucsok, Chief Operating Officer, and Steve Fox, Vice President of Sales, are recognized for their remarkable achievements and expertise in the field.
  • "We're pleased to have our team members included in the Top 25 Medical Device Executives for 2024," said Thomas Sandgaard, CEO of Zynex.
  • "The Healthcare Technology Report's rankings include peers from some of the largest and most innovative companies in the medical device space.

Muscle Stimulator Market Projected to Reach $925.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Freitag, Mai 3, 2024
TENS, Pain, Brain, Lactic acid, Inflammation, Stroke, Mobile device, Investment, EMS, Acceleration, Functional electrical stimulation, Hope, Sport, MENS, Traction, Table, System, Omron, Intelligence, Injury, Nerve, Pain management, BMAC, Optimism, Physical fitness, Electrical muscle stimulation, NMES, Movement, Athlete, Regeneration, Tetraplegia, Quality of life, Growth, Medical device

However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.

Key Points: 
  • However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.
  • This market scenario highlights a collective movement toward embracing muscle stimulator technologies for enhanced physical well-being and recovery.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Muscle Stimulator Market.
  • "Dive into the Muscle Stimulator Market Landscape: Explore 194 Pages of Insights, 922 Tables, and 26 Figures"

Muscle Stimulator Market Projected to Reach $925.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Freitag, Mai 3, 2024
TENS, Pain, Brain, Lactic acid, Inflammation, Stroke, Mobile device, Investment, EMS, Acceleration, Functional electrical stimulation, Hope, Sport, MENS, Traction, Table, System, Omron, Intelligence, Injury, Nerve, Pain management, BMAC, Optimism, Physical fitness, Electrical muscle stimulation, NMES, Movement, Athlete, Regeneration, Tetraplegia, Quality of life, Growth, Medical device

However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.

Key Points: 
  • However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.
  • This market scenario highlights a collective movement toward embracing muscle stimulator technologies for enhanced physical well-being and recovery.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Muscle Stimulator Market.
  • "Dive into the Muscle Stimulator Market Landscape: Explore 194 Pages of Insights, 922 Tables, and 26 Figures"

Nura Pain Clinics Announces New Edina Clinic Renovations to Optimize Patient Care

Retrieved on: 
Donnerstag, Mai 2, 2024
Capitol, Pain, Health, Pain management, Patient, Investment, Chronic pain, Nura, Birth control

EDINA, Minn., May 2, 2024 /PRNewswire/ -- Nura Pain Clinics, a subsidiary of the Capitol Pain family of practices, proudly announce the completion of a remodel to its Edina clinic located at 7400 France Avenue South. The renovation includes dedicating an additional 3,500 square feet of existing space to its surgery center, enhancing patient care capabilities.

Key Points: 
  • EDINA, Minn., May 2, 2024 /PRNewswire/ -- Nura Pain Clinics , a subsidiary of the Capitol Pain family of practices, proudly announce the completion of a remodel to its Edina clinic located at 7400 France Avenue South.
  • "This remodel allows us to see more patients as efficiently as possible, ensuring they get timely access to the care they need," said Dr. David Schultz, chief medical officer of Nura Pain Clinics.
  • Nura, Minnesota's foremost multidisciplinary pain management practice, continues to see an increased demand for its pain management services.
  • For more information on Nura Pain Clinics and its focus on pain management, visit nuraclinics.com .

EQS-News: Lindis Blood Care Announces Positive Top-Line Results from Clinical Certification Study REMOVE with CATUVAB® to Enable Autologous Blood Transfusions in Cancer Surgeries

Retrieved on: 
Freitag, Mai 3, 2024
FDA, Cancer, Prostate, Cell, Risk, Blood, Filter, CE marking, Cytokine, Trauma, Immunosuppression, Intensive care medicine, MD, Carcinoma, PILOT, Pain management, Patient, Lung, Teaching hospital, Clinical trial, IBS, Medical imaging

Convincing safety profile supports use of CATUVAB® during high blood loss cancer surgeries.

Key Points: 
  • Convincing safety profile supports use of CATUVAB® during high blood loss cancer surgeries.
  • Following these positive results, Company has initiated process to receive CE Mark in Europe and FDA conformity in the US.
  • Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, announced today excellent top-line results from the REMOVE certification study, a confirmatory open-label, multicenter clinical study, that enrolled more than 130 patients to assess CATUVAB® for use during intraoperative blood salvage (IBS) procedures in cancer surgeries.
  • CATUVAB® is designed to reliably remove cells from EpCAM (epithelial cell adhesion molecule)-positive tumors from the blood of cancer patients.

EQS-News: Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB® at NATA24 Annual Symposium

Retrieved on: 
Freitag, Mai 3, 2024
Cancer, Safety, Blood, Immunosuppression, Intensive care medicine, Pain management, Patient, Teaching hospital, Lymphocyte, IBS, Medical device

Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, today announces that top line results of its certification study REMOVE assessing the Company’s medical device for the removal of tumor cells from intraoperative blood during high-blood loss surgeries will be presented at the NATA24 Annual Symposium.

Key Points: 
  • Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, today announces that top line results of its certification study REMOVE assessing the Company’s medical device for the removal of tumor cells from intraoperative blood during high-blood loss surgeries will be presented at the NATA24 Annual Symposium.
  • The symposium will take place in Bologna, Italy between April 18 – 20, 2024.
  • CATUVAB® aims to ensure that cancer patients receive their own blood, minimizing the risks associated with allogenic (donor) blood transfusions.
  • Following the positive study outcome, CATUVAB® is aimed for approval in the EU and US in accordance with Medical Device Regulations.